<i>In vitro</i> activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD 2007–18)

Abstract Background Current antimicrobial susceptibility/resistance data versus skin and soft tissue infection (SSTI) pathogens help to guide empirical treatment using topical antimicrobials. Objectives To assess the in vitro activity resistance rates of fusidic acid, mupirocin, ozenoxacin comparator agents against isolated from patients with SSTIs Canada. Methods SSTI isolates MSSA (n = 422), MRSA 283) Streptococcus pyogenes 46) obtained CANWARD 2007–18 were tested CLSI broth microdilution. Fusidic acid low-level was defined as an MIC ≥2 mg/L high-level ≥512 mg/L. Mupirocin 2–256 Results Low-level 10.9% 1.7%, respectively. 10.6% 3.5%, High-level mupirocin identified 1.4% 14.1% MRSA, Versus MSSA, demonstrated MIC50 MIC90 0.004 0.25 mg/L, Against inhibited all at ≤0.5 including ciprofloxacin MICs &amp;gt;2 clarithromycin-resistant, clindamycin-resistant, acid-resistant mupirocin-resistant isolates. Conclusions We conclude that exceeded 10% for both while ≤3.5%. MRSA. Ozenoxacin is active resistant fluoroquinolones, macrolides, clindamycin, mupirocin.